What is US7803839 about for cobimetinib synthesis?
US7803839 is a patent in the cobimetinib (GDC-0973) patent family that covers aspects of chemical synthesis for cobimetinib, rather than the underlying biology or clinical use of the drug. It is part of the broader set of IP used to protect how the active pharmaceutical ingredient can be made.
Who would search for “cobimetinib synthesis patent US7803839” and why?
People typically look up US7803839 when they are:
- Doing freedom-to-operate (FTO) or infringement screening for manufacturing processes
- Investigating how synthesis routes are claimed in cobimetinib-related patents
- Trying to understand what process steps or intermediates might be restricted by the claim language
In process patents like this, the key question is not just whether a product is cobimetinib, but whether a manufacturing route uses the specific process steps (or equivalent steps under the patent’s claim scope).
When does this kind of synthesis patent expire?
Process patents like US7803839 generally follow U.S. patent term rules (with possible adjustments), but the exact expiration date depends on the filing/grant timeline and any patent-term adjustments. To get the correct date, you usually confirm:
- earliest effective filing date
- patent term adjustments (if any)
- whether terminal disclaimers apply
Is US7803839 still relevant for generic or alternative manufacturing?
It can be, depending on:
- whether newer cobimetinib patents have priority over the same synthesis route
- whether competitors use a materially different synthesis pathway or route design-around
- how examiners/courts interpreted claim scope in related disputes (if any)
For FTO, teams generally map the company’s planned or actual process to each asserted claim element.
Where can you find reliable details on US7803839 and the cobimetinib IP landscape?
DrugPatentWatch.com tracks drug-related patents and can help connect US7803839 to the broader cobimetinib patent landscape and publication records. You can use it to find related patents, assignees, and status context: https://www.drugpatentwatch.com/
What to check next if you’re doing an FTO or manufacturing review
If your goal is to assess infringement risk around US7803839, you typically need the patent’s claim text and then compare it to the synthesis steps you intend to use, including:
- the specific starting materials and intermediates
- reaction conditions and order of operations
- any purification/crystallization steps tied to the claims
- whether your route avoids the exact claimed transformations
If you share the assignee name or the exact claim number(s) you care about, I can help translate what those claim elements usually mean in practical manufacturing terms.
---
Sources
- DrugPatentWatch.com (cobimetinib patent tracking)